Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT07221188

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Led by GlaxoSmithKline · Updated on 2026-04-16

1250

Participants Needed

43

Research Sites

119 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.

CONDITIONS

Official Title

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Able and willing to understand and sign a written informed consent form prior to starting study procedures
  • Age 18 through 75 years at enrollment
  • History or presence of two or more of the five components of metabolic syndrome as defined by the American Heart Association
  • History or presence of known or suspected metabolic dysfunction-associated steatohepatitis (MASH) with evidence of fibrosis
Not Eligible

You will not qualify if you...

  • ALT or AST levels equal to or greater than five times the upper limit of normal
  • Total bilirubin equal to or greater than 1.3 mg/dL unless isolated increase due to Gilbert's syndrome with direct bilirubin 20% or less of total
  • Serum albumin 3.5 grams per deciliter or lower
  • International normalized ratio (INR) equal to or greater than 1.3 unless due to therapeutic anticoagulation
  • Alkaline phosphatase equal to or greater than two times the upper limit of normal
  • Platelet count below 140,000 per cubic millimeter, with possible enrollment if between 110,000 and 140,000 after medical review
  • Serum creatinine equal to or greater than 1.5 mg/dL or creatinine clearance 60 mL/min/1.73 m2 or less
  • Alpha-fetoprotein equal to or greater than 20 ng/mL
  • HbA1c equal to or greater than 9.0%
  • Model for End-Stage Liver Disease (MELD) score 12 or higher unless elevated without liver dysfunction
  • Phosphatidylethanol (PEth) equal to or greater than 80 ng/mL at screening
  • Known co-infection with HIV, Hepatitis B, C, D, or E viruses
  • Chronic liver disease from other causes including alcoholic liver disease, portal hypertension, viral hepatitis, cirrhosis, or decompensated liver disease
  • Current or history of excessive alcohol intake for 3 months or more within the 12 months before screening

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 43 locations

1

GSK Investigational Site

Arcadia, California, United States, 91006

Actively Recruiting

2

GSK Investigational Site

Covina, California, United States, 91723

Actively Recruiting

3

GSK Investigational Site

Los Angeles, California, United States, 90057

Actively Recruiting

4

GSK Investigational Site

Santa Maria, California, United States, 93458

Actively Recruiting

5

GSK Investigational Site

Cape Coral, Florida, United States, 33914

Actively Recruiting

6

GSK Investigational Site

Doral, Florida, United States, 33016

Actively Recruiting

7

GSK Investigational Site

Hialeah, Florida, United States, 33016

Actively Recruiting

8

GSK Investigational Site

Inverness, Florida, United States, 34452

Actively Recruiting

9

GSK Investigational Site

Jacksonville, Florida, United States, 32216

Actively Recruiting

10

GSK Investigational Site

Kissimmee, Florida, United States, 34744

Actively Recruiting

11

GSK Investigational Site

Lakeland, Florida, United States, 33803

Actively Recruiting

12

GSK Investigational Site

Maitland, Florida, United States, 32751

Actively Recruiting

13

GSK Investigational Site

Miami, Florida, United States, 33135

Actively Recruiting

14

GSK Investigational Site

Miami, Florida, United States, 33155

Actively Recruiting

15

GSK Investigational Site

Miami, Florida, United States, 33156

Actively Recruiting

16

GSK Investigational Site

Miami, Florida, United States, 33184

Actively Recruiting

17

GSK Investigational Site

Miami Lakes, Florida, United States, 33014

Actively Recruiting

18

GSK Investigational Site

Ocala, Florida, United States, 34471

Actively Recruiting

19

GSK Investigational Site

Palmetto Bay, Florida, United States, 33157

Actively Recruiting

20

GSK Investigational Site

Topeka, Kansas, United States, 66606

Actively Recruiting

21

GSK Investigational Site

Springfield, Missouri, United States, 62703

Actively Recruiting

22

GSK Investigational Site

St Louis, Missouri, United States, 63141

Actively Recruiting

23

GSK Investigational Site

Jersey City, New Jersey, United States, 07059

Actively Recruiting

24

GSK Investigational Site

East Syracuse, New York, United States, 13057

Actively Recruiting

25

GSK Investigational Site

New York, New York, United States, 10036

Actively Recruiting

26

GSK Investigational Site

Morehead City, North Carolina, United States, 28557

Actively Recruiting

27

GSK Investigational Site

Akron, Ohio, United States, 44320

Actively Recruiting

28

GSK Investigational Site

Springboro, Ohio, United States, 45066

Actively Recruiting

29

GSK Investigational Site

Austin, Texas, United States, 78745

Actively Recruiting

30

GSK Investigational Site

Austin, Texas, United States, 78759

Actively Recruiting

31

GSK Investigational Site

Brownsville, Texas, United States, 78526

Actively Recruiting

32

GSK Investigational Site

Dallas, Texas, United States, 75243

Actively Recruiting

33

GSK Investigational Site

DeSoto, Texas, United States, 75115

Actively Recruiting

34

GSK Investigational Site

Richmond, Texas, United States, 77406

Actively Recruiting

35

GSK Investigational Site

San Antonio, Texas, United States, 78215

Actively Recruiting

36

GSK Investigational Site

San Antonio, Texas, United States, 78229

Actively Recruiting

37

GSK Investigational Site

Seabrook, Texas, United States, 77586

Actively Recruiting

38

GSK Investigational Site

Tomball, Texas, United States, 77375

Actively Recruiting

39

GSK Investigational Site

Waco, Texas, United States, 76710

Actively Recruiting

40

GSK Investigational Site

Waco, Texas, United States, 76712

Actively Recruiting

41

GSK Investigational Site

West Jordan, Utah, United States, 84088

Actively Recruiting

42

GSK Investigational Site

Manassas, Virginia, United States, 20110

Actively Recruiting

43

GSK Investigational Site

Seattle, Washington, United States, 98105

Actively Recruiting

Loading map...

Research Team

U

US GSK Clinical Trials Call Center

CONTACT

E

EU GSK Clinical Trials Call Center

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH | DecenTrialz